Previous close | 40.73 |
Open | 40.82 |
Bid | 40.62 x 300 |
Ask | 40.70 x 300 |
Day's range | 40.45 - 40.96 |
52-week range | 29.85 - 45.00 |
Volume | |
Avg. volume | 1,348,754 |
Market cap | 5.169B |
Beta (5Y monthly) | 1.25 |
PE ratio (TTM) | 19.37 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Dr. Helen Torley, president and chief executive officer, is scheduled to present and host investor meetings at the following investor conferences:
Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") today reported its financial and operating results for the fourth quarter and full year ended December 31, 2023 and provided an update on its recent corporate activities and outlook.
Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its fourth quarter and full year 2023 financial and operating results on Tuesday, February 20, 2024, following the close of trading.